Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4191.30 +0.5% SILVER 57.23 +0.1% COPPER 6.57 +0.2% OIL 98.88 +0.9% PALLADIUM 1114.25 −1.3% MSV 0.570 +0.0% CCMM 0.520 +7.2% MON 0.385 −6.1% OMI 0.250 +0.0% BUFF 0.800 +2.6% FEO 0.640 −1.5% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% BVA 0.780 +2.6% ONAU 0.530 +1.9% FMR 0.225 +0.0% GSVR 0.350 +2.9% PHNM 0.345 +1.5% SLG 5.65 −1.1% CASA 0.060 +0.0% GOLD 4191.30 +0.5% SILVER 57.23 +0.1% COPPER 6.57 +0.2% OIL 98.88 +0.9% PALLADIUM 1114.25 −1.3% MSV 0.570 +0.0% CCMM 0.520 +7.2% MON 0.385 −6.1% OMI 0.250 +0.0% BUFF 0.800 +2.6% FEO 0.640 −1.5% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% BVA 0.780 +2.6% ONAU 0.530 +1.9% FMR 0.225 +0.0% GSVR 0.350 +2.9% PHNM 0.345 +1.5% SLG 5.65 −1.1% CASA 0.060 +0.0%
Production / Operations

Cresco Labs Launches Flagship Flower Brand in Germany

By The Northwire Desk — AI Analysis Nov 12, 2025 · 06:30 CL · 1.68 Cresco Labs Inc.
CL · Price

Executive Summary

  • Cresco Labs announced the commercial launch of its branded cannabis flower in Germany, marking the company’s first entry into the European Union market.
  • The rollout includes three signature flower products manufactured by EU‑GMP partner Blossom in Portugal and sold via prescription through licensed German pharmacies.
  • The expansion is positioned as a pilot to gather regulatory and market insights that will guide future growth decisions across Europe.

Key Details

  • Geographic Expansion: First EU commercial entry – product now available in Germany.
  • Product Offering: Three signature flower products, each targeted to specific patient effects.
  • Manufacturing Partner: Blossom (EU‑GMP certified facility in Portugal).
  • Distribution Channel: Prescription sales through licensed pharmacies across Germany.
  • Strategic Rationale: Leverage Cresco’s brand portfolio and operational expertise to capture growth in one of the world’s fastest‑growing regulated cannabis markets.
  • CEO Quote: “After extensive work understanding the European landscape, we’re confident that Cresco can deliver meaningful value… Our objective is to use these insights to guide future growth decisions in evolving markets.” – Charlie Bachtell, CEO.

Notable Quotes

“Our objective is to use these insights to guide future growth decisions in evolving markets.” – Charlie Bachtell, CEO, Cresco Labs.

Read the original news release →

More from Cresco Labs Inc.

Jun 08, 2026 · 06:00

Cresco Labs Closes US$50 Million Revolving Credit Facility with Needham Bank

Financings May 27, 2026 · 06:30

DEA Registration Puts Federal Imprimatur on Cresco’s Medical Operations, but Texas Setback Clouds Growth Ambitions

Regulatory May 11, 2026 · 06:30

Texas Regulator Pulls Back Cresco’s Conditional License, Clouding a Key Growth Catalyst

Regulatory May 08, 2026 · 06:30

Cresco Labs Q1 Earnings Show Revenue Stagnation Despite Regulatory Tailwinds and Texas License Award

Earnings Apr 23, 2026 · 13:24

Federal Rescheduling Validates Business Model, But Debt Overhang Remains Key Risk

Regulatory Apr 02, 2026 · 19:21

Cresco Labs receives Texas medical cannabis licence

Other